BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Ultimate Trader

1 year 30%, 2 years 40% and *3 years 40%

*Across 3 years $3395.52 only $1697.76

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,047.15
0.81%
US Tech 100
20,607.20
1.07%
Dow Jones
44,782.00
-0.29%
Brent Oil
71.695
-0.27%
Bitcoin
96,013.76
0.16%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Nanobiotix SA (NBTX) Quote

Nanobiotix SA

Nanobiotix SA (NBTX)

NASDAQ
3.14
-0.09
(-2.79%)
Closed December 02 4:00PM
Delayed by 15 minutes
3.14
0.00
(0.00%)
After Hours: 6:31PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.14
Bid
3.10
Ask
3.25
Volume
16,560
3.02 Day's Range 3.2117
0.00 52 Week Range 0.00
Market Cap
147.999M
Previous Close
3.23
Open
3.18
Last Trade
1
@
3.21
Last Trade Time
Financial Volume
$ 51,683
VWAP
3.1209
Average Volume (3m)
-
Shares Outstanding
47,133,328
Dividend Yield
-
PE Ratio
-3.34
Earnings Per Share (EPS)
-0.84
Revenue
36.21M
Net Profit
-39.7M

About Nanobiotix SA

Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying ... Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.nanobiotix.com
Headquarters
Paris, Paris, Fra
Founded
-
Nanobiotix SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NBTX. The last closing price for Nanobiotix was $3.23. Over the last year, Nanobiotix shares have traded in a share price range of $ 0.00 to $ 0.00.

Nanobiotix currently has 47,133,328 shares outstanding. The market capitalization of Nanobiotix is $152.24 million. Nanobiotix has a price to earnings ratio (PE ratio) of -3.34.

Ask ADVFN Intelligence (AI)

NBTX Latest News

More News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

November 13 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

November 12 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

October 31 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

October 11 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 18 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 18 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 04 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 03 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 08 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

July 09 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SNTISenti Biosciences Inc
$ 10.09
(367.13%)
128.73M
PPBTPurple Biotech Ltd
$ 8.359
(149.15%)
47.77M
GELSGelteq Ltd
$ 3.8205
(92.95%)
1.4M
FOSLFossil Group Inc
$ 2.35
(60.96%)
29.52M
FGLFounder Group Limited
$ 4.48
(60.00%)
473.38k
MONDMondee Holdings Inc
$ 0.375
(-47.20%)
2.85M
JYDJayud Global Logistics Ltd
$ 0.6701
(-39.63%)
1.81M
TOIIWOncology Institute Inc
$ 0.0122
(-35.45%)
929
IDAIT Stamp Inc
$ 0.4565
(-33.84%)
12.78M
FOXXFoxx Development Holdings Inc
$ 3.32
(-29.96%)
43.58k
SMCISuper Micro Computer Inc
$ 42.00
(28.68%)
263.23M
XTIAXTI Aerospace Inc
$ 0.04745
(5.68%)
177.38M
NVDANVIDIA Corporation
$ 138.63
(0.27%)
170.53M
INTCIntel Corporation
$ 23.93
(-0.50%)
150.48M
RGTIRigetti Computing Inc
$ 3.035
(-0.49%)
134.81M

NBTX Discussion

View Posts
Monksdream Monksdream 8 months ago
NBTX 10Q due 4/3
👍️0
Monksdream Monksdream 8 months ago
NBTX under $10
👍️0
Monksdream Monksdream 1 year ago
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0
Monksdream Monksdream 1 year ago
July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0

Your Recent History

NASDAQ
NBTX
Nanobiotix
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 50%* for Small Cap Pro

1 year 30%, 2 years 40% and *3 years 50%

*Across 3 years $2158.56 only $1079.28